SCHEMBL5048834

SCHEMBL5048834

CS(=O)(=O)c1ccc(Nc2ncnc(OC3CCNCC3)c2C#N)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 20/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890870 0.87 GPR119 (0.69) GPR119
SCHEMBL5048753 0.86 GPR119 (0.56) GPR119
SCHEMBL6065464 0.84 GPR119 (0.44) GPR119
SCHEMBL13022058 0.82 GPR119 (0.68) GPR119
SCHEMBL389011 0.82 GPR119 (0.80) GPR119
SCHEMBL5048440 0.82 GPR119 (0.53) GPR119
SCHEMBL3170972 0.81 GPR119 (0.65) GPR119
SCHEMBL5052397 0.80 GPR119 (0.51) GPR119
SCHEMBL16384744 0.78 GPR119 (0.62) GPR119
SCHEMBL5049657 0.78 GPR119 (0.42) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed